CRIS Current Research Information System

PANTANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.781
AS - Asia 3.757
EU - Europa 2.647
AF - Africa 318
SA - Sud America 207
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.737
CN - Cina 1.085
SG - Singapore 1.009
VN - Vietnam 970
IT - Italia 696
GB - Regno Unito 473
DE - Germania 338
SE - Svezia 334
HK - Hong Kong 238
IN - India 171
NL - Olanda 152
BR - Brasile 150
KR - Corea 149
CI - Costa d'Avorio 131
RU - Federazione Russa 130
IE - Irlanda 107
FR - Francia 102
TG - Togo 60
SC - Seychelles 57
UA - Ucraina 56
FI - Finlandia 55
ZA - Sudafrica 50
JP - Giappone 34
AT - Austria 33
EE - Estonia 32
BG - Bulgaria 31
AR - Argentina 28
CA - Canada 28
CH - Svizzera 28
BE - Belgio 25
JO - Giordania 19
ID - Indonesia 18
NG - Nigeria 15
PL - Polonia 15
MX - Messico 13
IR - Iran 12
ES - Italia 11
CZ - Repubblica Ceca 9
BD - Bangladesh 8
EC - Ecuador 8
AU - Australia 7
CL - Cile 7
PH - Filippine 7
TR - Turchia 7
CO - Colombia 5
IQ - Iraq 4
LB - Libano 4
RO - Romania 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
CY - Cipro 2
GH - Ghana 2
IL - Israele 2
KZ - Kazakistan 2
LT - Lituania 2
MY - Malesia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
VE - Venezuela 1
ZM - Zambia 1
Totale 10.720
Salva come PNG Salva come JPEG
Città #
Singapore 662
Ashburn 520
Chandler 417
Southend 398
Fairfield 331
Hefei 327
Hong Kong 238
Ho Chi Minh City 226
Bologna 220
Woodbridge 163
Hanoi 157
Seoul 149
Ann Arbor 148
Beijing 144
Seattle 143
Dallas 140
Wilmington 138
Dong Ket 136
Houston 132
Abidjan 131
Cambridge 115
Princeton 109
Dublin 107
Santa Clara 97
Boardman 81
New York 72
Los Angeles 67
Lomé 60
Milan 55
Nanjing 46
Bremen 45
Munich 40
Hyderabad 39
Westminster 38
Helsinki 35
Padova 33
Haiphong 32
Tokyo 32
Sofia 31
Turin 31
Jinan 30
Bengaluru 29
Frankfurt am Main 28
Berlin 27
Redmond 27
Buffalo 25
Jacksonville 25
Redondo Beach 25
Brussels 24
Shenyang 23
Changsha 22
Fabriano 22
Redwood City 22
San Diego 22
Vienna 22
Saint Petersburg 21
Bern 20
Nuremberg 20
Amman 19
Amsterdam 18
Florence 18
São Paulo 17
Ha Long 15
Abeokuta 14
Guangzhou 14
Medford 14
Nanchang 14
Zhengzhou 14
Falkenstein 13
Tianjin 13
Biên Hòa 12
Hebei 12
Lappeenranta 12
Rome 12
Chicago 11
Falls Church 11
Jakarta 11
Quận Bình Thạnh 11
Tongling 11
Toronto 11
Washington 11
Da Nang 10
Monmouth Junction 10
Ninh Bình 10
Thái Nguyên 10
Dearborn 9
Dongguan 9
Jiaxing 9
London 9
Phoenix 9
Quận Một 9
Shanghai 9
Wuhan 9
Atlanta 8
Brooklyn 8
Charlotte 8
Chengdu 8
Des Moines 8
Mülheim 8
Norwalk 8
Totale 6.995
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 662
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 266
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 229
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 229
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 206
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 205
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 198
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 186
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 181
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 181
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 179
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 173
Thalidomide maintenance in multiple myeloma: certainties and controversies. 171
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 169
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 168
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 166
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 166
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 166
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 161
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 159
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 158
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 157
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 157
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 155
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 151
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 150
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 150
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 148
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 148
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 148
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 147
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 147
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 146
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 145
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 144
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 140
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 132
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 131
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 129
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 128
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 124
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 123
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 122
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 122
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 122
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 121
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 120
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 118
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 117
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 114
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 107
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 107
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 100
null 98
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 96
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 94
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 93
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 86
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 79
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 73
Proteasome inhibitors: Bortezomib in multiple myeloma 73
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 73
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 71
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 60
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 51
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 50
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 44
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 41
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 33
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 33
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 23
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 21
Totale 10.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021586 0 0 0 0 0 44 27 61 82 33 31 308
2021/20221.192 136 52 60 93 89 51 27 82 48 136 208 210
2022/20231.597 141 222 63 262 108 134 46 97 269 54 121 80
2023/2024603 41 83 34 51 47 152 27 83 13 19 31 22
2024/20251.973 113 193 172 173 207 78 144 68 51 228 177 369
2025/20263.145 538 1.031 461 455 516 144 0 0 0 0 0 0
Totale 10.948